Deutsche Bank AG Has $8 Million Stake in Scholar Rock Holding Co. (NASDAQ:SRRK)

Deutsche Bank AG boosted its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 364.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 185,003 shares of the company's stock after purchasing an additional 145,211 shares during the period. Deutsche Bank AG owned about 0.20% of Scholar Rock worth $7,996,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of SRRK. JPMorgan Chase & Co. grew its holdings in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after acquiring an additional 379 shares during the period. Nisa Investment Advisors LLC grew its holdings in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after acquiring an additional 1,031 shares during the period. KBC Group NV acquired a new stake in Scholar Rock during the 4th quarter worth about $131,000. Moody Aldrich Partners LLC acquired a new stake in Scholar Rock during the 4th quarter worth about $1,201,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Scholar Rock by 29.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,850 shares of the company's stock worth $858,000 after acquiring an additional 4,457 shares during the period. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Mo Qatanani sold 68,510 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the completion of the transaction, the insider now directly owns 111,084 shares of the company's stock, valued at $4,154,541.60. This represents a 38.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Edward H. Myles sold 7,809 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $287,605.47. Following the completion of the transaction, the chief financial officer now directly owns 140,740 shares of the company's stock, valued at approximately $5,183,454.20. This represents a 5.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 255,231 shares of company stock valued at $9,220,236 over the last three months. Corporate insiders own 13.30% of the company's stock.

Scholar Rock Price Performance

SRRK stock opened at $30.55 on Friday. The company has a market capitalization of $2.90 billion, a P/E ratio of -13.00 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a 52-week low of $6.76 and a 52-week high of $46.98. The business has a 50-day simple moving average of $31.19 and a two-hundred day simple moving average of $35.87.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). Research analysts expect that Scholar Rock Holding Co. will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Wednesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.